REGENXBIO (NASDAQ:RGNX) Cut to Sell at StockNews.com

StockNews.com lowered shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a sell rating in a report released on Thursday.

RGNX has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of REGENXBIO in a research note on Wednesday, January 15th. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th. Morgan Stanley restated an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Finally, Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Price Performance

RGNX opened at $7.88 on Thursday. REGENXBIO has a fifty-two week low of $6.56 and a fifty-two week high of $28.80. The company has a market capitalization of $390.41 million, a P/E ratio of -1.57 and a beta of 1.28. The firm’s fifty day moving average price is $8.42 and its two-hundred day moving average price is $10.38.

Institutional Trading of REGENXBIO

A number of hedge funds have recently modified their holdings of RGNX. FMR LLC grew its position in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. nVerses Capital LLC raised its stake in REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares in the last quarter. GAMMA Investing LLC grew its position in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in REGENXBIO during the 3rd quarter worth $140,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.